Latest scientific publications

  • Functional recovery of islet β cells in human type 2 diabetes: Transcriptome signatures unveil therapeutic approaches.

  • Auteurs Suleiman M, Sawatani T, Tesi M, Yi X, Papadopoulou T, Rufer C, Lytrivi M, Bosi E, Burdet F, Fantuzzi F, De Luca C, Sebastiani G, Saponaro C, Pugliese LA, Del Guerra S, Pocai A, De Simone P, Ghinolfi D, Boggi U, Kessler C, Grieco GE, Fignani D, Kerr-Conte J, Pattou F, Nacher M, Montanya E, Mourad N, Buemi A, Citi V, Martelli A, Benedetti G, Calderone V, Rossi L, Paolicchi A, Cardarelli F, Dotta F, Eizirik DL, Ibberson M, Marchetti P, Cnop M, Marselli L
  • Auteurs (entité) Lytrivi Maria
  • Revue Sci Adv
  • Date de publication 2025-10
Functional recovery of islet β cells in human type 2 diabetes: Transcriptome signatures unveil therapeutic approaches.
  • Rationale and Methodological Approach Underlying the Development of the Sequential Organ Failure Assessment (SOFA)-2 Score: A Consensus Statement.

  • Auteurs Moreno R, Rhodes A, Ranzani O, Salluh JIF, Berger-Estilita J, Coopersmith CM, Juffermans NP, Laffey J, Reinikainen M, Neto AS, Tavares M, Timsit JF, Arias Lopez MDP, Arulkumaran N, Azoulay E, Chaudhuri D, De Lange D, De Waele J, Dos Santos CC, Du B, Einav S, Ferrer R, Fujii T, Gershengorn HB, Haniffa R, Hasan MS, Hollenberg S, Ippolito M, Jung C, Kirov M, Lakbar I, Lipman J, Liu V, Lobo SM, Martin GS, Metnitz P, Myatra SN, Oczkowski S, Paiva JA, Paruk F, Pekkarinen PT, Pilcher D, Piquilloud L, Pölkki A, Prescott HC, Blaser AR, Rezende E, Robba C, Rochwerg B, Schenck EJ, Sendagire C, Siaw-Frimpong M, Simpkin AJ, Soares M, Summers C, Szczeklik W, Takala J, Vincent JL, Wendon J, Zampieri FG, Shankar-Hari M, Singer M
  • Auteurs (entité) Vincent Jean Louis
  • Revue JAMA Netw Open
  • Date de publication 2025-10
Rationale and Methodological Approach Underlying the Development of the Sequential Organ Failure Assessment (SOFA)-2 Score: A Consensus Statement.
  • Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).

  • Auteurs Malorni L, Tyekucheva S, Gombos A, Hasler-Strub U, Zamagni C, Chakiba-Brugère C, Colleoni M, Mueller A, Minisini AM, Taylor D, Salmon JP, Gallerani E, Cariello A, Fontana A, Roschitzki-Voser H, Kammler R, Ruepp B, Loi S, Viale G, Regan MM, Brain E, Biganzoli L
  • Auteurs (entité) GOMBOS ANDREA
  • Revue Ann Oncol
  • Date de publication 2025-10
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17).
  • Toward the development of an innovative pharmacological compound employing peptides for EGFR-mediated drug delivery in anaplastic thyroid carcinoma.

  • Auteurs Kahvecioglu ZC, Vandecasteele S, Bougard M, Rasson O, Nachtergael A, Duez P, Nonclercq D, Remmelink M, Laurent S, Saussez S, Burtea C
  • Auteurs (entité) Remmelink Myriam
  • Revue Biochem Pharmacol
  • Date de publication 2025-10
Toward the development of an innovative pharmacological compound employing peptides for EGFR-mediated drug delivery in anaplastic thyroid carcinoma.
  • Evolving paradigms in pulmonary hypertension: Highlights of the 6 <sup>th</sup> French Pulmonary Hypertension Network Meeting.

  • Auteurs Boucly A, Beauvais A, Lacoste-Palasset T, Jevnikar M, Riou M, Solinas S, Antigny F, Bauer F, Bertoletti L, Bonnet D, Chaouat A, Cottin V, D'Alto M, Delcroix M, Dewavrin MG, Guignabert C, Hascoet S, Kiely DG, Jaïs X, Jutant EM, Lamblin N, Mercier O, Moceri P, Noel-Savina E, Picard F, Trembath R, Tromeur C, Vachiery JL, Savale L, Humbert M, Sitbon O, Montani D
  • Auteurs (entité) Vachiery Jean Luc
  • Revue Respir Med Res
  • Date de publication 2025-10
Evolving paradigms in pulmonary hypertension: Highlights of the 6 <sup>th</sup> French Pulmonary Hypertension Network Meeting.
  • Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group.

  • Auteurs Brandão M, Prisciandaro E, Xenophontos E, Mariolo A, Sadeghi AH, Filippi AR, Levy A, Bandura A, Caramella C, Dickhoff C, de Margerie-Mellon C, Faivre-Finn C, Portik D, Sanchez-Lorente D, De Ruysscher D, Smit E, Gobbini E, Fadel E, Ruffini E, Olmetto E, Cortiula F, Bahce I, Houda I, Opitz I, Naidoo J, Edwards J, Remon J, Benitez JC, Trujillo JC, Derks J, Amrane K, Hartemink KJ, Stathopoulos K, Hendriks LEL, Iglesias M, Occhipinti M, Guckenberger M, Giaj Levra N, Girard N, Reguart N, Mercier O, Bironzo P, Hofman P, Petersen RH, De Angelis R, Abgral R, Terrisse S, Popat S, Pierret T, Blum TG, Ricardi U, Dionisi V, Berghmans T, Dingemans AC
  • Auteurs (entité) BERGHMANS THIERRY
  • Revue Lung Cancer
  • Date de publication 2025-10
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group.
Bordet hospital

Jules Bordet Institute

View all of Jules Bordet's scientific publications

Erasme hospital

Erasme Hospital

View all of Erasme's scientific publications

Huderf hospital

Queen Fabiola Children's Hospital

View all scientific publications from the Queen Fabiola Children's Hospital